Trial reportCancer imaging : the official publication of the International Cancer Imaging Society2018
Trial report in Cancer imaging : the official publication of the International Cancer Imaging Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01918592 (PET/MRI and Biomarkers in Clinical Staging of Bladder Cancer and in the Estimation of Neoadjuvant Chemotherapy Response Prior to Radical Cystectomy), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PET/MRI and Biomarkers in Clinical Staging of Bladder Cancer and in the Estimation of Neoadjuvant Chemotherapy Response Prior to Radical Cystectomy
Who cites it
10 citing papers in PubMed, 29 citations in OpenAlex.
- Beyond Visualization: Advanced Imaging, Theragnostics and Biomarker Integration in Urothelial Bladder Cancer.Cancers · 2025Review
- Acetate Metabolism in Urological Health and Disease.Serican journal of medicine · 2024Article
- Performance ofiScience · 2024Article
- Differential performance of imaging modalities predicting pathological response to neoadjuvant chemotherapy in urothelial bladder cancer: a systematic review and meta-analysis.Central European journal of urology · 2024Review
- PET Imaging in Bladder Cancer: An Update and Future Direction.Pharmaceuticals (Basel, Switzerland) · 2023Review
- The Role of Molecular Imaging in a Muscle-Invasive Bladder Cancer Patient: A Narrative Review in the Era of Multimodality Treatment.Diagnostics (Basel, Switzerland) · 2021Review
- Role of PET/CT in muscle-invasive bladder cancer.Translational andrology and urology · 2020Review
- The Role of Imaging in Bladder Cancer Diagnosis and Staging.Diagnostics (Basel, Switzerland) · 2020Review
- The Role of 18F-FDG PET/CT in Guiding Precision Medicine for Invasive Bladder Carcinoma.Frontiers in oncology · 2020Review
- Synergy of PET and MR imaging in the local and regional staging of bladder cancer.Therapeutic advances in urologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate the accuracy of
methodsEighteen patients were prospectively enrolled. Fifteen treatment naive patients underwent
resultsThe sensitivity, specificity and accuracy of
conclusions
trial registrationClinicalTrials.gov Identifier: NCT01918592 , registered August 8 2013.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.